Onco-Innovations announced interim results from liver microsome metabolism studies of ONC010's active ingredient across human, rat, and dog models. The findings show metabolism primarily via cytochrome P450 enzymes with species-specific differences, supporting continued preclinical development. Further studies, including hepatocyte tests and nanoparticle degradation, are ongoing to inform dosing and regulatory plans. The results align with expectations and help advance ONC010 toward clinical trials.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Macy's will report its Q2 fiscal 2026 earnings on September 10, with analysts expecting adjusted EPS of $0.37 and net sales of $4.81 billion, both above company guidance. The retailer's turnaround strategy focuses on strengthening its core stores, gr...
Wells Fargo lowered its price target for Casey's General Stores to $750 from $960 after the company reported a 3.2% same-store sales growth in Q1, missing analyst expectations. Despite the sales miss, Casey's posted revenue of $5.68 billion and EPS o...
